Compare C.H. Robinson Worldwide, Inc. (CHRW) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C.H. Robinson Worldwide, Inc. vs McKesson Corporation — how do they compare? C.H. Robinson Worldwide, Inc. trades at $147.88 (market cap $16.96B), while McKesson Corporation trades at $884.82 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 6.2× C.H. Robinson Worldwide, Inc.'s market cap, and C.H. Robinson Worldwide, Inc. pays the higher dividend (1.74%). Which is the better fit depends on your goals.
| CHRW | MCK | |
|---|---|---|
Market Cap | $16.96B | $105.14B |
Sector | Industrials | Health |
52-Week High | $209.42 | $995.69 |
52-Week Low | $118.77 | $659.01 |
Enterprise Value | $18.78B | $111.67B |
Dividend Yield | 1.74% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHRW trades at $147.68, down 0.41% with bearish technical signals, though recent earnings beats and strong profitability metrics provide fundamental support. The company reported Q2 2026 EPS of $1.61, beating expectations, with revenue of $16.23B in 2025 and net income margin improving to 3.73%. Analyst consensus remains positive with a $193 price target, while recent news highlights dividend declarations and institutional buying activity.
Outlook remains cautiously optimistic given earnings momentum and solid ROE of 37.12%, though technical weakness and legal challenges pose near-term risks. The stock offers growth potential with reasonable valuation (P/E 27.7) but faces headwinds from freight demand volatility and competitive pressures in logistics.
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
